Relmada Therapeutics, Inc. (RLMD) NASDAQ

2.26

+0.25(+12.44%)

Updated at October 20 04:00PM

Currency In USD

Valuation

Market Cap15.69M
Enterprise Value11.83M
P/E Ratio-1.11
PEG Ratio-0.1
Price/Sales Ratio0
Price/Book Ratio4.7
Enterprise/Revenue0
Enterprise/EBITDA-1.05

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterJune 30, 2025

Profitability

Profit Margin0
Operating Margin0

Management Effectiveness

Return On Assets-3.21
Return On Equity-2.23

Income Statement

Revenue0
Revenue/Share0
Gross Profit0
EBITDA-79.98M
Net Income-79.98M
Diluted EPS-2.65

Balance Sheet

Total Cash20.62M
Total Cash/Share0.62
Total Debt0
Total Debt/Equity0
Current Ratio4.11
Book Value Per Share0.48

Price History

52-Week Change149.04
52-Week High3.98
52-Week Low0.24
Moving Average 50 Days1.44
Moving Average 200 Days0.71

Statistics

Average Volume752,453
Shares Outstanding33.19M
% Held by Institutions15.98

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor1:4
Last Split DateSeptember 30, 2019